Morgan Stanley Call 150 6MK 16.01.../ DE000MB9KN75 /
14.11.2024 8:32:10 | Изменение-0.011 | Бид11:14:38 | Предложение11:14:38 | Базовый актив | Цена исполнения | Дата истечения | Тип опциона |
---|---|---|---|---|---|---|---|
0.081EUR | -11.96% | 0.089 Величина цены спроса: 2,000 |
0.114 Величина цены предложения: 2,000 |
MERCK CO. D... | 150.00 - | 16.01.2026 | Call |
GlobeNewswire
31.07
Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
GlobeNewswire
17.07
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease a...
GlobeNewswire
09.07
Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination ...
GlobeNewswire
25.06
Qure.ai announces strategic investment by Merck Global Health Innovation Fund to boost innovation of...
GlobeNewswire
18.06
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for ...
GlobeNewswire
06.06
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepin...
GlobeNewswire
03.06
Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, ...
GlobeNewswire
29.05
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio fo...
GlobeNewswire
07.05
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
06.05
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Person...
GlobeNewswire
06.03
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Can...
- Первая страница
- Назад
- 1
- 2
- 3
- 4
- Следующий
- Последняя страница